Mira Pharmaceuticals Reports Preclinical Study Results For Oral Ketamine Analog, Ketamir-2
Portfolio Pulse from Benzinga Newsdesk
Mira Pharmaceuticals announced positive preclinical study results for its oral ketamine analog, Ketamir-2. The study highlights Ketamir-2's potential as a superior alternative to traditional ketamine, offering ease of use and better patient compliance without being a controlled substance under DEA rules.
June 10, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mira Pharmaceuticals' positive preclinical results for Ketamir-2 suggest potential for a superior alternative to traditional ketamine, which could drive future growth and investor interest.
The positive preclinical results for Ketamir-2 indicate potential for a new product that could outperform traditional ketamine. This could lead to increased investor interest and potential future growth for Mira Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100